HomeCompareBOVNF vs EPRT

BOVNF vs EPRT: Dividend Comparison 2026

BOVNF yields 60.82% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BOVNF wins by $613.8K in total portfolio value
10 years
BOVNF
BOVNF
● Live price
60.82%
Share price
$3.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$678.1K
Annual income
$160,128.39
Full BOVNF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — BOVNF vs EPRT

📍 BOVNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOVNFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOVNF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOVNF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOVNF
Annual income on $10K today (after 15% tax)
$5,169.37/yr
After 10yr DRIP, annual income (after tax)
$136,109.13/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, BOVNF beats the other by $124,913.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOVNF + EPRT for your $10,000?

BOVNF: 50%EPRT: 50%
100% EPRT50/50100% BOVNF
Portfolio after 10yr
$371.2K
Annual income
$86,649.62/yr
Blended yield
23.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

BOVNF
No analyst data
Altman Z
10.4
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOVNF buys
0
EPRT buys
0
No recent congressional trades found for BOVNF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOVNFEPRT
Forward yield60.82%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$678.1K$64.3K
Annual income after 10y$160,128.39$13,170.85
Total dividends collected$563.7K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BOVNF vs EPRT ($10,000, DRIP)

YearBOVNF PortfolioBOVNF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$16,782$6,081.62$11,212$512.01+$5.6KBOVNF
2$27,495$9,538.25$12,689$692.09+$14.8KBOVNF
3$44,024$14,604.90$14,521$944.30+$29.5KBOVNF
4$68,961$21,855.37$16,841$1,302.88+$52.1KBOVNF
5$105,784$31,995.46$19,841$1,821.64+$85.9KBOVNF
6$159,058$45,869.04$23,818$2,587.47+$135.2KBOVNF
7$234,649$64,457.18$29,230$3,744.65+$205.4KBOVNF
8$339,944$88,869.20$36,816$5,540.38+$303.1KBOVNF
9$484,065$120,324.94$47,806$8,413.17+$436.3KBOVNF
10$678,078$160,128.39$64,324$13,170.85+$613.8KBOVNF

BOVNF vs EPRT: Complete Analysis 2026

BOVNFStock

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

Full BOVNF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this BOVNF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOVNF vs SCHDBOVNF vs JEPIBOVNF vs OBOVNF vs KOBOVNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.